Genetic Technologies (GTG) AI Stock Analysis

• Market Cap: AU$5.67M
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): 2.00
• Revenue Growth: -56.35%
• EPS Growth: 42.80%
• Country: AU
• Employees: 55
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 1,335,422,500
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: 0.04
• Price to Book (P/B): 5.85
• Price to Sales (P/S): 1.40
• P/FCF Ratio: -1.10
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): AU$43.79M

• Rating: 43 Neutral
• Price Target: ―

Genetic Technologies is currently facing financial challenges, with declining revenues and persistent losses as significant concerns. The stock shows a neutral technical trend and a negative valuation outlook due to ongoing losses. Improvements in financial performance and strategic actions towards profitability are necessary for a better stock outlook.

Genetic Technologies Business Overview & Revenue Model

Company Description

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

How the Company Makes Money

Genetic Technologies makes money through the sale of its genetic testing products and services. The company's primary revenue stream comes from the commercialization of its proprietary genetic risk assessment tests, which are sold directly to healthcare providers, clinics, and consumers. GTG also generates income by partnering with medical institutions and laboratories to distribute and utilize its testing technologies. Additionally, the company may engage in collaborations with pharmaceutical companies for research purposes, potentially leading to further revenue through licensing agreements or joint ventures.

Genetic Technologies Financial Statement Overview

Summary

Genetic Technologies faces significant financial challenges with declining revenues and persistent losses. The balance sheet shows moderate leverage, but declining equity poses risks to financial health. Cash flow management needs improvement to enhance liquidity and operational sustainability. Strategic focus on cost control and revenue growth is crucial for financial recovery.

Income Statement

Genetic Technologies has faced challenges in sustaining revenue, with a significant decline from the previous year, resulting in a negative revenue growth rate of approximately -25.9%. Both gross profit and net profit margins are negative, indicating cost challenges and profitability issues. Continued losses and negative EBIT and EBITDA margins highlight operational inefficiencies.

Balance Sheet

The company exhibits a low debt-to-equity ratio of approximately 0.48, suggesting manageable leverage. However, the return on equity is negative due to consistent losses, impacting shareholder value. With an equity ratio of approximately 29.6%, the company maintains a moderate level of financial stability, but declining equity over the years is concerning.

Cash Flow

Operating cash flows remain negative, reflecting ongoing operational struggles. The free cash flow growth rate is slightly positive, but still negative in absolute terms, highlighting cash flow challenges. The operating cash flow to net income ratio is favorable, indicating efficient cash use relative to net losses. However, the company needs to improve cash generation to support growth and reduce financing reliance.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.66M	10.35M	6.79M	120.55K	837.87K
Gross Profit	3.90M	6.01M	6.47M	-240.47K	736.43K
EBITDA	-11.43M	-11.20M	-7.20M	-6.58M	-5.87M
Net Income	-12.02M	-11.75M	-7.13M	-7.08M	-6.29M
Balance Sheet
Total Assets	6.19M	14.86M	20.80M	22.97M	15.63M
Cash, Cash Equivalents and Short-Term Investments	1.02M	7.87M	11.73M	20.90M	14.22M
Total Debt	875.19K	532.85K	652.53K	204.04K	481.79K
Total Liabilities	4.36M	3.69M	4.37M	1.44M	1.64M
Stockholders Equity	1.83M	11.16M	16.43M	21.53M	13.99M
Cash Flow
Free Cash Flow	-9.71M	-9.74M	-5.76M	-6.94M	-5.75M
Operating Cash Flow	-9.68M	-9.72M	-5.66M	-6.30M	-5.71M
Investing Cash Flow	114.90K	-311.94K	-3.49M	-642.00K	64.79K
Financing Cash Flow	2.82M	5.92M	-279.06K	13.94M	18.36M

Genetic Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.04
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Neutral
• RSI: Negative
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:GTG, the sentiment is Positive. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.04, indicating a neutral trend. The MACD of >-0.01 indicates Neutral momentum. The RSI at 100.00 is Negative, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:GTG.

Genetic Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IBX	49 Neutral	AU$13.25M	-2.39	―	―	-47.02%	94.37%
LDX	46 Neutral	AU$225.85M	-16.15	-111.23%	―	12.96%	40.81%
BDX	45 Neutral	AU$47.85M	-6.31	-97.79%	―	―	23.85%
RHY	44 Neutral	AU$53.96M	-11.63	-501.54%	―	―	56.42%
GTG	43 Neutral	AU$5.67M	-0.55	―	―	-56.35%	42.80%
IIQ	38 Underperform	AU$54.90M	-6.18	-37.78%	―	2.33%	12.50%

Genetic Technologies Corporate Events

Genetic Technologies Director Anthony Hartman Steps Down

Genetic Technologies Limited has announced that director Anthony Hartman has ceased to be a director of the company as of 9 September 2025. The filing with the ASX indicates that Hartman holds no relevant interests in the company’s securities or related contracts, suggesting the board change is procedural in nature and does not immediately alter the company’s capital structure or disclosed ownership profile.

Genetic Technologies Appoints New Director, Discloses Major Indirect Shareholding

Genetic Technologies Limited has notified the ASX that Steven Nicols has been appointed as a director of the company effective 19 December 2025, in accordance with listing rule 3.19A.1 and relevant Corporations Act provisions. The filing discloses that Nicols holds no shares directly in Genetic Technologies but has an indirect relevant interest through his role at Benelong Capital Partners Pty Ltd, which holds 26,493,450 ordinary shares, a sizable stake that could influence governance dynamics and shareholder representation at the company.

Genetic Technologies Reshapes Board and Tightens Governance Ahead of Relisting

Genetic Technologies has announced the resignation of director Anthony Hartman, effective 9 September 2025, and the appointment of experienced ASX-listed company director Steve Nicols as a non-executive director from 19 December 2025, bolstering the board’s corporate and insolvency expertise as it advances recapitalisation and relisting plans. The company also acknowledged previous non-compliance with ASX disclosure rules related to Hartman’s resignation and interests notice, and has introduced enhanced governance measures, including formal director appointment and resignation checklists and stricter notification procedures, which the board believes will ensure future compliance as it navigates acquisitions, recapitalisation, and its return to the market.

Genetic Technologies Announces Change in Company Secretary

Genetic Technologies Limited announced the resignation of Mr. Mark Ziirsen as the Joint Company Secretary, effective December 1, 2025. Ms. Priyamvada (Pia) Rasal will continue as the sole Company Secretary, handling communications between the company and ASX, ensuring compliance with ASX Listing Rule 12.6. This change in company secretarial roles is expected to maintain the company’s operational continuity and regulatory compliance.